IMDX
Insight Molecular Diagnostics Inc.NASDAQ
Healthcare • Diagnostics & Research
Factor tilt: Micro-Cap Blend
$2.49+1.22%
Close Nov 6, 2026
- Market cap
- $91.51M
- 1 month
- -24.1%
- 3 months
- -47.8%
- 1 year
- -62.6%
- 52-week range
- $2.46$8.48
- Dividend
- No dividends on record
- Short interest
- 9.5% of float949.5K shares · settled Oct 15, 2026 · -2.4% since Sep 30, 2026 · FINRA
Fundamentals · trailing 12 months to Jun 30, 2026
- Revenue
- $1.67M
- Net income
- -$49.36M
- Free cash flow
- -$30.88M
- Book value
- —
- Total debt
- $2.63M
- P/E
- —
- Price / sales
- 54.8×
- Price / book
- —
- FCF yield
- -33.7%
- Net margin
- -2,955.6%
EODHD (TTM) · as of Nov 6, 2026
End-of-day close from stored market data, not a live quote.
About Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests.
Read more
It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers GraftAssureCore test, a blood test designed to measure dd-cfDNA using a novel PCR-based measurement platform, for potential patient registrants; GraftAssureIQ, a transplant monitoring assay to measure the donor-derived cell-free DNA; and GraftAssureDx, a decentralized transplant monitoring levels of donor-derived cell-free DNA in plasma following kidney transplantation to aid in the assessment of the probability of allograft rejection at the time of testing in conjunction with standard clinical assessments. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. The company was formerly known as OncoCyte Corporation and changed its name to Insight Molecular Diagnostics Inc. in June 2025. Insight Molecular Diagnostics Inc. was incorporated in 2009 and is based in Nashville, Tennessee.
- Website
- imdxinc.com
- Headquarters
- Nashville, TN, United States
- Employees
- 55
- Listed
- Jan 4, 2016
- Fiscal year ends
- December
Company profile from EODHD, stored Oct 26, 2026.
Quarterly results
The last 8 fiscal quarters as reported (EODHD). Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Jun 2026filed Aug 10, 2026 | $239.0K | -53.9% | 65.7% | -$11.4M | -$11.3M |
| Mar 2026filed May 13, 2026 | $32.0K | -98.5% | -1,892.2% | -$10.3M | -$4.3M |
| Dec 2025filed Mar 26, 2026 | $1.1M | -23.4% | 43.5% | -$10.0M | -$23.0M |
| Sep 2025filed Nov 10, 2025 | $260.0K | +126.1% | 53.5% | -$11.0M | -$10.9M |
| Jun 2025filed Aug 11, 2025 | $518.0K | +398.1% | 67.6% | -$9.8M | -$9.7M |
| Mar 2025filed May 12, 2025 | $2.1M | +1,114.8% | 62.0% | -$6.8M | -$6.7M |
| Dec 2024filed Mar 24, 2025 | $1.5M | — | 40.0% | -$33.6M | -$33.5M |
| Sep 2024filed Nov 12, 2024 | $115.0K | -73.2% | 43.5% | -$13.5M | -$13.5M |
Short-interest history
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
Compare the reported short exposure around the dates you bought, sold or watched IMDX. A long position benefits from price rises; a short position benefits from falls. A change in these counts does not predict either move.
Settlement Oct 15, 2026
949,512 shares short
-23,517 shares (-2.4%) vs Sep 30, 2026
9.5% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
973,029 shares short
-19,445 shares (-2%) vs Sep 15, 2026
9.4% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
992,474 shares short
+61,733 shares (+6.6%) vs Aug 31, 2026
9.9% of the stored float. Published Sep 24, 2026.
Settlement Aug 31, 2026
930,741 shares short
-158,353 shares (-14.5%) vs Aug 14, 2026
9.3% of the stored float. Published Sep 10, 2026.
Settlement Aug 14, 2026
1,089,094 shares short
+15,327 shares (+1.4%) vs Jul 31, 2026
Share of float unavailable. Published Aug 25, 2026.
Settlement Jul 31, 2026
1,073,767 shares short
-172,235 shares (-13.8%) vs Jul 15, 2026
Share of float unavailable. Published Aug 11, 2026.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
Dividends and stock splits
See the recorded cash amounts and dates behind IMDX’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
Cash-dividend records
No qualified cash-dividend records are stored. This does not establish that the company pays no dividend.
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
Split history
1 for 20 · reverse split
Effective Jul 25, 2023
Each 20 pre-split shares become 1 post-split share.
Source: EODHD
Up to six stored split dates through Nov 7, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workPortfolio context
Sign in to see your position size
We’ll show you if IMDX is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
Smart money context
Holder IQ: LOW
5 smart-money holders: institutions with a high Holder IQ
Q2 2026, filed Sep 22, 2026
Insider context
Sentiment: unknown
No recent insider trades detected.
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
No directional recent-activity label is available. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 1
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
No directional recent-activity label is available. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Largest 13-F holders · Q2 2026
40 filers reported a long position in IMDX for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
The top 10 hold
95.3%
of the 18.5M shares 13-F filers reported
Moves vs Q1 2026
6 added3 trimmed
1 new
Net shares held
+7.4%
across the 9 holders with a comparable Q1 2026 book
| Rank | Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|---|
| 1 | BROADWOOD CAPITAL INC | $74.8M · 12.7M shares | 12.7M | +6.3% |
| 2 | AWM Investment Company, Inc. | $16.7M · 2.8M shares | 2.8M | +1.1% |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | $4.3M · 735.8K shares | 735.8K | +37% |
| 4 | Family Office Research LLC | $2.2M · 368.8K shares | 368.8K | +189.8% |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | $1.5M · 256.9K shares | 256.9K | -2% |
| 6 | FNY Investment Advisers, LLC | $1.1M · 182.6K shares | 182.6K | -26.2% |
| 7 | JANE STREET GROUP, LLC | $930.3K · 157.7K shares | 157.7K | New |
| 8 | BlackRock, Inc. | $888.1K · 150.5K shares | 150.5K | +11.2% |
| 9 | VANGUARD FIDUCIARY TRUST CO | $735K · 124.6K shares | 124.6K | -6% |
| 10 | STATE STREET CORP | $543.5K · 92.1K shares | 92.1K | +81.5% |
Sign in to see each holder’s Holder IQ, factor-adjusted Holder IQ and rank, and compare these holders with all scored filers. Available on every plan.
Sign in5% holder filings (13D / 13G)
Holders of more than 5% of IMDX file with the SEC within days. A 13D holder may seek to influence the company; a 13G holder is passive. Each holder’s latest filing from the last three years.
| Filed | Holder | % of class |
|---|---|---|
| Apr 27, 2026 | BROADWOOD PARTNERS, L.P.13D · activist · amended | 39.7% |
Get the Full Analysis for IMDX
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.